USD 0.8086
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ASRT | -0.2 | 0.1 | -4.4 | -23.7 | -50.1 | -4.4 | -63.1 | -82.7 | -98.9 | -94.6 |
| S&P 500 | 0.5 | 2.1 | 2.4 | 5.5 | 10.1 | 25.8 | 38.7 | 84.0 | 198.2 | 34547.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ASRT |
| name | Assertio Holdings, Inc. |
| price | 0.8086 |
| changes percentage | -0.1728 |
| change | -0.0014 |
| day low | 0.79 |
| day high | 0.81 |
| year high | 1.8 |
| year low | 0.73 |
| market cap | 77203349 |
| price avg 50 | 0.8996 |
| price avg 200 | 1.0887 |
| exchange | NASDAQ |
| volume | 412137 |
| avg volume | 799348 |
| open | 0.8 |
| previous close | 0.81 |
| eps | -0.44 |
| pe | -1.84 |
| earnings announcement | 2025-03-10T20:00:00.000+0000 |
| shares outstanding | 95477800 |
| timestamp | 2025-01-23 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001808665 | |||
| revenue | 152069000 | 156234000 | -2.67 |
| gross profit | 125049000 | 137486000 | -9.05 |
| gross profit ratio | 0.82 | 0.88 | -6.55 |
| research and development expenses | 2843000 | 0 | NaN |
| operating expenses | 368585000 | 79394000 | 364.25 |
| interest income | 0 | 7961000 | -100.00 |
| interest expense | 3380000 | 7961000 | -57.54 |
| ebitda | -222447000 | 72535000 | -406.68 |
| ebitdaratio | -1.46 | 0.58 | -350.56 |
| operating income | -243536000 | 57814000 | -521.24 |
| operating income ratio | -1.6 | 0.37 | -532.78 |
| net income | -331942000 | 109625000 | -402.80 |
| net income ratio | -2.18 | 0.7 | -411.09 |
| eps | -4.67 | 2.33 | -300.43 |
Revenue Growth: revenue decreased to 152 million in 2023 from 156 million in 2022 representing a change of -2.67%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 125 million in 2023 from 137 million in 2022 representing a change of -9.05%. This indicates a sales profitability decline, which is a negative sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -222 million in 2023 from 73 million in 2022 representing a change of -406.68%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -244 million in 2023 from 58 million in 2022 representing a change of -521.24%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -332 million in 2023 from 110 million in 2022 representing a change of -402.8%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -4.67 in 2023 from -4.67 in 2022 representing a change of -300.43%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses increased to 3 million in 2023 from 0 million in 2022 representing a change of nan%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 369 million in 2023 from 79 million in 2022 representing a change of 364.25%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001808665 | |||
| revenue | 29204000 | 31126000 | -6.17 |
| gross profit | 21654000 | 22237000 | -2.62 |
| gross profit ratio | 0.74 | 0.71 | 3.79 |
| research and development expenses | 1005000 | 798000 | 25.94 |
| operating expenses | 24702000 | 25854000 | -4.46 |
| interest income | 887000 | 842000 | 5.34 |
| interest expense | 761000 | 758000 | 0.40 |
| ebitda | 4595000 | 3944000 | 16.51 |
| ebitdaratio | 0.16 | 0.13 | 24.17 |
| operating income | -3048000 | -3617000 | 15.73 |
| operating income ratio | -0.1 | -0.12 | 10.19 |
| net income | -2921000 | -3674000 | 20.50 |
| net income ratio | -0.1 | -0.12 | 15.26 |
| eps | -0.03 | -0.04 | 20.73 |
Revenue Growth: revenue decreased to 29 million in 2024Q3 from 31 million in 2024Q2 representing a change of -6.17%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 22 million in 2024Q3 from 22 million in 2024Q2 representing a change of -2.62%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 1 million in 2024Q3 from 1 million in 2024Q2 representing a change of 25.94%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Income: Operating income decreased to -3 million in 2024Q3 from -4 million in 2024Q2 representing a change of 15.73%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -3 million in 2024Q3 from -4 million in 2024Q2 representing a change of 20.5%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Operating Expenses: Operating Expenses decreased to 25 million in 2024Q3 from 26 million in 2024Q2 representing a change of -4.46%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 5 million in 2024Q3 from 4 million in 2024Q2 representing a change of 16.51%. The increase in EBITDA indicates improved operational efficiency and profitability.
Earnings per Share (EPS): EPS increased to -0.03 in 2024Q3 from -0.03 in 2024Q2 representing a change of 20.73%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001808665 | |||
| total assets | 286419000 | 413913000 | -30.80 |
| total liabilities | 148416000 | 188188000 | -21.13 |
| total equity | 138003000 | 225725000 | -38.86 |
| cash and cash equivalents | 73441000 | 64941000 | 13.09 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 268000 | -100.00 |
| total current assets | 171062000 | 132262000 | 29.34 |
| total non current assets | 115357000 | 281651000 | -59.04 |
| total current liabilities | 93443000 | 95316000 | -1.97 |
| total non current liabilities | 54973000 | 92872000 | -40.81 |
| common stock | 9000 | 5000 | 80.00 |
| retained earnings | -651543000 | -319601000 | -103.86 |
| total debt | 40912000 | 66873000 | -38.82 |
Total Assets: Total Assets decreased to 286 million in 2023 from 414 million in 2022 representing a change of -30.8%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 138 million in 2023 from 226 million in 2022 representing a change of -38.86%. This indicates a decrease in shareholders' equity.
Retained Earnings: Retained Earnings decreased to -652 million in 2023 from -320 million in 2022 representing a change of -103.86%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 148 million in 2023 from 188 million in 2022 representing a change of -21.13%. This indicates a decrease in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 73 million in 2023 from 65 million in 2022 representing a change of 13.09%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 171 million in 2023 from 132 million in 2022 representing a change of 29.34%. This indicates a better liquidity position.
Total Current Liabilities: Total Current Liabilities decreased to 93 million in 2023 from 95 million in 2022 representing a change of -1.97%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 80.0%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 41 million in 2023 from 67 million in 2022 representing a change of -38.82%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001808665 | |||
| total assets | 275999000 | 279443000 | -1.23 |
| total liabilities | 145481000 | 147290000 | -1.23 |
| total equity | 130518000 | 132152999 | -1.24 |
| cash and cash equivalents | 37981000 | 44735000 | -15.10 |
| short term investments | 50598000 | 43644000 | 15.93 |
| long term investments | 0 | 0 | NaN |
| total current assets | 181156000 | 177852000 | 1.86 |
| total non current assets | 94843000 | 101591000 | -6.64 |
| total current liabilities | 90104000 | 92184000 | -2.26 |
| total non current liabilities | 55377000 | 55105999 | 0.49 |
| common stock | 9000 | 9000 | 0.00 |
| retained earnings | -662648000 | -659727000 | -0.44 |
| total debt | 39714000 | 40648000 | -2.30 |
Total Assets: Total Assets decreased to 276 million in 2024Q3 from 279 million in 2024Q2 representing a change of -1.23%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 131 million in 2024Q3 from 132 million in 2024Q2 representing a change of -1.24%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 38 million in 2024Q3 from 45 million in 2024Q2 representing a change of -15.1%. This indicates a decrease in available liquid assets.
Retained Earnings: Retained Earnings decreased to -663 million in 2024Q3 from -660 million in 2024Q2 representing a change of -0.44%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 145 million in 2024Q3 from 147 million in 2024Q2 representing a change of -1.23%. This indicates a decrease in overall liabilities.
Short Term Investments: Short Term Investments increased to 51 million in 2024Q3 from 44 million in 2024Q2 representing a change of 15.93%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 181 million in 2024Q3 from 178 million in 2024Q2 representing a change of 1.86%. This indicates a better liquidity position.
Total Current Liabilities: Total Current Liabilities decreased to 90 million in 2024Q3 from 92 million in 2024Q2 representing a change of -2.26%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 40 million in 2024Q3 from 41 million in 2024Q2 representing a change of -2.3%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001808665 | |||
| net change in cash | 8500000 | 28131000 | -69.78 |
| operating cash flow | 49604000 | 78598000 | -36.89 |
| free cash flow | 48976000 | 78324000 | -37.47 |
| capital expenditure | -628000 | -274000 | -129.20 |
| depreciation and amortization | 28227000 | 33396000 | -15.48 |
| deferred income tax | 76201000 | -80375000 | 194.81 |
| stock based compensation | 9158000 | 7504000 | 22.04 |
| accounts payables | -29348000 | -10208000 | -187.50 |
| inventory | -4973000 | -6593000 | 24.57 |
| acquisitions net | 1950000 | -42399000 | 104.60 |
| investments in property plant and equipment | -628000 | -274000 | -129.20 |
| net cash used for investing activites | 3097000 | -42673000 | 107.26 |
| debt repayment | -10500000 | -4834000 | -117.21 |
| common stock issued | 0 | 7020000 | -100.00 |
| common stock repurchased | -7898000 | -838000 | -842.48 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -44201000 | -7794000 | -467.12 |
| cash at end of period | 73441000 | 64941000 | 13.09 |
| accounts receivables | 48669000 | -996000 | 4986.45 |
| cash at beginning of period | 64941000 | 36810000 | 76.42 |
Net Change in Cash: Net Change in Cash decreased to 8 million in 2023 from 28 million in 2022 representing a change of -69.78%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to 50 million in 2023 from 79 million in 2022 representing a change of -36.89%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to 49 million in 2023 from 78 million in 2022 representing a change of -37.47%. This indicates a decrease in cash generated after accounting for capital expenditures.
Deferred Income Tax: Deferred Income Tax increased to 76 million in 2023 from -80 million in 2022 representing a change of 194.81%. This indicates that the company's tax liability for future periods has increased.
Stock-Based Compensation: Stock-Based Compensation increased to 9 million in 2023 from 8 million in 2022 representing a change of 22.04%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 29 million in 2023 from 10 million in 2022 representing a change of -187.5%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 49 in 2023 from -1 million in 2022 representing a change of 4986.45%. This suggests that the company is less capable of collecting payments from its customers.
Capital Expenditure: Capital Expenditure decreased to -1 million in 2023 from 0 million in 2022 representing a change of -129.2%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001808665 | |||
| operating cash flow | -35000 | 7387000 | -100.47 |
| free cash flow | -35000 | 7387000 | -100.47 |
| capital expenditure | 0 | 0 | NaN |
| depreciation and amortization | 6711000 | 6711000 | 0.00 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 1296000 | 1408000 | -7.95 |
| accounts receivables | -5031000 | 2696000 | -286.61 |
| accounts payables | -3628000 | -1493000 | -143.00 |
| inventory | -1813000 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | 0 | NaN |
| net cash used for investing activites | -6709000 | -43320000 | 84.51 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 281000 | -75000 | 474.67 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -10000 | -75000 | 86.67 |
| net change in cash | -6754000 | -36008000 | 81.24 |
| cash at end of period | 37981000 | 44735000 | -15.10 |
| cash at beginning of period | 44735000 | 80743000 | -44.60 |
Net Change in Cash: Net Change in Cash increased to -7 million in 2024Q3 from -36 million in 2024Q2 representing a change of 81.24%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Stock-Based Compensation: Stock-Based Compensation decreased to 1 million in 2024Q3 from 1 million in 2024Q2 representing a change of -7.95%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Receivables: Accounts Receivables decreased to -5 million in 2024Q3 from 3 million in 2024Q2 representing a change of -286.61%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to 0 million in 2024Q3 from 7 million in 2024Q2 representing a change of -100.47%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to 0 million in 2024Q3 from 7 million in 2024Q2 representing a change of -100.47%. This indicates a decrease in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables increased to 4 million in 2024Q3 from 1 million in 2024Q2 representing a change of -143.0%. This indicates that the company has increased its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 2.14 | 3.32 | -35.59 |
| net income per share | -4.67 | 2.33 | -300.37 |
| operating cash flow per share | 0.7 | 1.67 | -58.24 |
| free cash flow per share | 0.69 | 1.67 | -58.62 |
| cash per share | 1.03 | 1.38 | -25.16 |
| book value per share | 1.94 | 4.8 | -59.54 |
| tangible book value per share | 0.38 | 0.59 | -36.35 |
| shareholders equity per share | 1.94 | 4.8 | -59.54 |
| interest debt per share | 0.62 | 1.59 | -60.83 |
| market cap | 76003170 | 202117200 | -62.40 |
| enterprise value | 43474170 | 204049200 | -78.69 |
| pe ratio | -0.23 | 1.84 | -112.42 |
| price to sales ratio | 0.5 | 1.29 | -61.37 |
| pocfratio | 1.53 | 2.57 | -40.42 |
| pfcf ratio | 1.55 | 2.58 | -39.86 |
| pb ratio | 0.55 | 0.9 | -38.49 |
| ptb ratio | 0.55 | 0.9 | -38.49 |
| ev to sales | 0.29 | 1.31 | -78.11 |
| enterprise value over ebitda | -0.2 | 2.81 | -106.95 |
| ev to operating cash flow | 0.88 | 2.6 | -66.24 |
| ev to free cash flow | 0.89 | 2.61 | -65.93 |
| earnings yield | -4.37 | 0.54 | -905.24 |
| free cash flow yield | 0.64 | 0.39 | 66.29 |
| debt to equity | 0.3 | 0.3 | 0.07 |
| debt to assets | 0.14 | 0.16 | -11.59 |
| net debt to ebitda | 0.15 | 0.03 | 449.02 |
| current ratio | 1.83 | 1.39 | 31.93 |
| interest coverage | -72.05 | 7.26 | -1092.16 |
| income quality | -0.15 | 0.72 | -120.84 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.43 | 0.28 | 54.72 |
| research and ddevelopement to revenue | 0.02 | 0 | NaN |
| intangibles to total assets | 0.39 | 0.48 | -18.74 |
| capex to operating cash flow | 0.01 | 0.0 | 263.16 |
| capex to revenue | 0.0 | 0.0 | 135.47 |
| capex to depreciation | 0.02 | 0.01 | 171.17 |
| stock based compensation to revenue | 0.06 | 0.05 | 25.38 |
| graham number | 14.29 | 15.87 | -9.96 |
| roic | -1.64 | 0.64 | -357.80 |
| return on tangible assets | -1.9 | 0.51 | -473.41 |
| graham net net | -0.29 | -1.75 | 83.63 |
| working capital | 77619000 | 36946000 | 110.09 |
| tangible asset value | 26671000 | 27729000 | -3.82 |
| net current asset value | 22646000 | -55926000 | 140.49 |
| invested capital | 190990000 | 235686000 | -18.96 |
| average receivables | 46510000 | 44859000 | 3.68 |
| average payables | 9715000 | 6338000 | 53.28 |
| average inventory | 25691000 | 10592500 | 142.54 |
| days sales outstanding | 114.4 | 105.96 | 7.96 |
| days payables outstanding | 181.54 | 116.64 | 55.65 |
| days of inventory on hand | 509.08 | 266.64 | 90.92 |
| receivables turnover | 3.19 | 3.44 | -7.38 |
| payables turnover | 2.01 | 3.13 | -35.75 |
| inventory turnover | 0.72 | 1.37 | -47.62 |
| roe | -2.41 | 0.49 | -595.27 |
| capex per share | 0.01 | 0.01 | 51.67 |
ROE: Return on Equity (ROE) decreased to -2.41 on 2023-12-31 from 0.49 on 2022-12-31, representing a change of -595.27%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -0.23 on 2023-12-31 from 1.84 on 2022-12-31, representing a change of -112.42%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 1.83 on 2023-12-31 from 1.39 on 2022-12-31, representing a change of 31.93%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.30 on 2023-12-31 from 0.30 on 2022-12-31, representing a change of 0.07%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| ASRT | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.31 | 0.33 | -6.29 |
| net income per share | -0.03 | -0.04 | 20.59 |
| operating cash flow per share | -0.0 | 0.08 | -100.47 |
| free cash flow per share | -0.0 | 0.08 | -100.47 |
| cash per share | 0.93 | 0.93 | 0.11 |
| book value per share | 1.37 | 1.39 | -1.35 |
| tangible book value per share | 0.4 | 0.35 | 15.07 |
| shareholders equity per share | 1.37 | 1.39 | -1.35 |
| interest debt per share | 0.42 | 0.43 | -2.36 |
| market cap | 112515360 | 113335600 | -0.72 |
| enterprise value | 114248360 | 109248600 | 4.58 |
| pe ratio | -9.63 | -7.71 | -24.87 |
| price to sales ratio | 3.85 | 3.64 | 5.81 |
| pocfratio | -3214.72 | 15.34 | -21052.97 |
| pfcf ratio | -3214.72 | 15.34 | -21052.97 |
| pb ratio | 0.86 | 0.86 | 0.52 |
| ptb ratio | 0.86 | 0.86 | 0.52 |
| ev to sales | 3.91 | 3.51 | 11.46 |
| enterprise value over ebitda | 24.86 | 27.7 | -10.24 |
| ev to operating cash flow | -3264.24 | 14.79 | -22171.62 |
| ev to free cash flow | -3264.24 | 14.79 | -22171.62 |
| earnings yield | -0.03 | -0.03 | 19.92 |
| free cash flow yield | -0.0 | 0.07 | -100.48 |
| debt to equity | 0.3 | 0.31 | -1.07 |
| debt to assets | 0.14 | 0.15 | -1.08 |
| net debt to ebitda | 0.38 | -1.04 | 136.40 |
| current ratio | 2.01 | 1.93 | 4.21 |
| interest coverage | -4.01 | -4.77 | 16.06 |
| income quality | 0.01 | -2.01 | 100.60 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.03 | 0.03 | 34.23 |
| intangibles to total assets | 0.33 | 0.35 | -5.57 |
| capex to operating cash flow | 0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0 | NaN |
| stock based compensation to revenue | 0.04 | 0.05 | -1.90 |
| graham number | 0.97 | 1.1 | -11.49 |
| roic | -0.02 | -0.02 | 17.02 |
| return on tangible assets | -0.02 | -0.02 | 21.89 |
| graham net net | -0.03 | -0.1 | 65.07 |
| working capital | 91052000 | 85668000 | 6.28 |
| tangible asset value | 38159000 | 33123000 | 15.20 |
| net current asset value | 35675000 | 30562000 | 16.73 |
| invested capital | 185197000 | 186560000 | -0.73 |
| average receivables | 42428500 | 41261500 | 2.83 |
| average payables | 14212000 | 15460500 | -8.08 |
| average inventory | 39434000 | 38841000 | 1.53 |
| days sales outstanding | 138.51 | 115.41 | 20.02 |
| days payables outstanding | 156.79 | 154.62 | 1.41 |
| days of inventory on hand | 474.29 | 395.68 | 19.87 |
| receivables turnover | 0.65 | 0.78 | -16.68 |
| payables turnover | 0.57 | 0.58 | -1.39 |
| inventory turnover | 0.19 | 0.23 | -16.57 |
| roe | -0.02 | -0.03 | 19.50 |
| capex per share | 0 | 0 | NaN |
ROE: Return on Equity (ROE) increased to -0.02 on 2024-09-30 Q3 from -0.03 on 2024-06-30 Q2, representing a change of 19.50%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -9.63 on 2024-09-30 Q3 from -7.71 on 2024-06-30 Q2, representing a change of -24.87%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 2.01 on 2024-09-30 Q3 from 1.93 on 2024-06-30 Q2, representing a change of 4.21%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.30 on 2024-09-30 Q3 from 0.31 on 2024-06-30 Q2, representing a change of -1.07%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-03 16:30:00
LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective December 23, 2024, the Compensation Committee of the Company's Board of Directors granted Mary Pietryga, the Company's newly-hired Senior Vice President, Chief Commercial Officer, 62,500 restricted stock units (“RSUs”) and 275,000 stock options (“options”).
Sentiment: Positive
Publish Date: 2024-12-17 08:30:00
LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee.
Sentiment: Negative
Publish Date: 2024-12-13 08:00:00
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon ® (eflapegrastim-xnst) injection when dosed the same day of chemotherapy for patients with early stage breast cancer (ESBC).
Sentiment: Positive
Publish Date: 2024-12-10 08:01:13
CTV, GRAB, ASRT, POWL and LUV have been added to the Zacks Rank #1 (Strong Buy) List on December 10, 2024.
Sentiment: Positive
Publish Date: 2024-11-29 06:36:09
MKTAY, ASRT, CHH, DRS and BRKL have been added to the Zacks Rank #1 (Strong Buy) List on November 29, 2024.
Sentiment: Negative
Publish Date: 2024-11-15 09:00:00
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that recently inverted its long equity position into that of a short interest in the publicly traded securities of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today called upon the Senate Committee on Health, Education, Labor & Pensions (the “Committee”) to investigate the evident product-related fraud at.
Sentiment: Positive
Publish Date: 2024-11-11 18:57:44
Call Start: 16:30 January 1, 0000 5:03 PM ET Assertio Holdings, Inc. (NASDAQ:ASRT ) Q3 2024 Earnings Conference Call November 11, 2024 04:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Brendan O'Grady - CEO Ajay Patel - SVP & CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Naz Rahman - Maxim Group Scott Henry - Alliance Global Partners Raghuram Selvaraju - H.C. Wainwright Operator Thank you for standing by.
Sentiment: Negative
Publish Date: 2024-11-11 18:11:09
Assertio (ASRT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.01 per share a year ago.
Sentiment: Positive
Publish Date: 2024-11-11 16:02:00
Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the third quarter ended September 30, 2024.
Sentiment: Negative
Publish Date: 2024-11-11 15:41:00
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that has inverted its long equity position into that of a short interest in the publicly traded securities of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today responded to the Company's attempt to deny, in its November 11, 2024, press release, the evident product-related fraud at Spectrum Pharmaceuticals, In.
Sentiment: Positive
Publish Date: 2024-11-11 07:30:00
Claims about Rolvedon and Assertio's Accounting Practices are False and Baseless Short-seller's Press Release is Another Improper Attempt to Enrich Himself at Assertio's Expense Company Considering Taking Legal and Regulatory Action LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today issued the following letter from Chief Executive Officer Brendan O'Grady in response to public comments made November 8, 2024 by a short-seller: To the members of the investment community, As many of you have been aware, Mr.
Sentiment: Negative
Publish Date: 2024-11-08 09:00:00
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that has now inverted its long equity position into that of a short interest in the publicly traded securities of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today released an open letter to Assertio stockholders. “Today, BHG has sadly been forced to issue a letter to Assertio stockholders, in light of the bo.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
